These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38283962)

  • 41. Cardiovascular and kidney benefits of SGLT-2is and GLP-1RAs according to baseline blood pressure in type 2 diabetes: a systematic meta-analysis of cardiovascular outcome trials.
    Kunutsor SK; Seidu S; Dey RS; Baidoo IK; Oulhaj A
    Scand Cardiovasc J; 2024 Dec; 58(1):2418086. PubMed ID: 39425977
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Longitudinal association of electrocardiogram abnormalities with major adverse cardiac events in people with Type 2 diabetes: the Hoorn Diabetes Care System cohort.
    Harms PP; Elders PPJM; Rutters F; Lissenberg-Witte BI; Tan HL; Beulens JWJ; Nijpels G; van der Heijden AA;
    Eur J Prev Cardiol; 2023 Jun; 30(8):624-633. PubMed ID: 36625405
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative effectiveness of team-based care with a clinical decision support system versus team-based care alone on cardiovascular risk reduction among patients with diabetes: Rationale and design of the D4C trial.
    Shi X; He J; Lin M; Liu C; Yan B; Song H; Wang C; Xiao F; Huang P; Wang L; Li Z; Huang Y; Zhang M; Chen CS; Obst K; Li W; Yang S; Yao G; Li X
    Am Heart J; 2021 Aug; 238():45-58. PubMed ID: 33957103
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review.
    Einarson TR; Acs A; Ludwig C; Panton UH
    Value Health; 2018 Jul; 21(7):881-890. PubMed ID: 30005761
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Patorno E; Htoo PT; Glynn RJ; Schneeweiss S; Wexler DJ; Pawar A; Bessette LG; Chin K; Everett BM; Kim SC
    Ann Intern Med; 2021 Nov; 174(11):1528-1541. PubMed ID: 34570599
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Severe obesity in a specialist type 2 diabetes outpatient clinic: an Australian retrospective cohort study.
    Thakur A; Sharma D; Gupta B; Kramadhari N; Rajagopal R; Simmons D; Piya MK
    BMC Endocr Disord; 2021 Mar; 21(1):55. PubMed ID: 33757476
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diabetes and cardiovascular disease risk screening model in community pharmacies in a developing primary healthcare system: a feasibility study.
    Alzubaidi HT; Chandir S; Hasan S; McNamara K; Cox R; Krass I
    BMJ Open; 2019 Nov; 9(11):e031246. PubMed ID: 31712336
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study.
    Jurado J; Ybarra J; Solanas P; Caula J; Gich I; Pou JM; Romeo JH
    J Am Acad Nurse Pract; 2009 Mar; 21(3):140-8. PubMed ID: 19302689
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.
    Palmer MJ; Machiyama K; Woodd S; Gubijev A; Barnard S; Russell S; Perel P; Free C
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD012675. PubMed ID: 33769555
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular Outcomes Among Patients with Type 2 Diabetes Newly Initiated on Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Other Antidiabetic Medications.
    Pineda ED; Liao IC; Godley PJ; Michel JB; Rascati KL
    J Manag Care Spec Pharm; 2020 May; 26(5):610-618. PubMed ID: 32347181
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of Multifactorial Treatment Targets and Relative Importance of Hemoglobin A1c, Blood Pressure, and Low-Density Lipoprotein-Cholesterol on Cardiovascular Diseases in Chinese Primary Care Patients With Type 2 Diabetes Mellitus: A Population-Based Retrospective Cohort Study.
    Wan EYF; Fung CSC; Yu EYT; Chin WY; Fong DYT; Chan AKC; Lam CLK
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862945
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.
    Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Eliasson B; Andersson Sundell K
    BMC Health Serv Res; 2018 Nov; 18(1):900. PubMed ID: 30486824
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries.
    Mosenzon O; Alguwaihes A; Leon JLA; Bayram F; Darmon P; Davis TME; Dieuzeide G; Eriksen KT; Hong T; Kaltoft MS; Lengyel C; Rhee NA; Russo GT; Shirabe S; Urbancova K; Vencio S;
    Cardiovasc Diabetol; 2021 Jul; 20(1):154. PubMed ID: 34315481
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Protective Effects of Home T2DM Treatment with Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-transporter-2 Inhibitors Against Intensive Care Unit Admission and Mortality in the Acute Phase of the COVID-19 Pandemic: A Retrospective Observational Study in Italy.
    Monda VM; Voci C; Strollo F; Passaro A; Greco S; Monesi M; Bigoni R; Porcellati F; Piani D; Satta E; Gentile S
    Diabetes Ther; 2023 Dec; 14(12):2127-2142. PubMed ID: 37801224
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Education programmes for people with chronic kidney disease and diabetes.
    Cashmore BA; Cooper TE; Evangelidis NM; Green SC; Lopez-Vargas P; Tunnicliffe DJ
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD007374. PubMed ID: 39171639
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of Heart Failure History at Baseline on Cardiovascular Effects of GLP-1 Receptor Agonists in Type 2 Diabetes: a Meta-analysis.
    Banerjee M; Maisnam I; Mukhopadhyay S
    Cardiovasc Drugs Ther; 2024 Aug; 38(4):739-746. PubMed ID: 36696050
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes.
    Yun JS; Ko SH
    Metabolism; 2021 Oct; 123():154838. PubMed ID: 34333002
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.